Afatinib

Wang K, et al. Sensors and Actuators B: Chemical, 2025, 426, 137056.

This study reports the synthesis and application of a novel afatinib-based theranostic fluorescent probe, AFNI-pH, designed for targeted cancer cell detection and real-time monitoring of intracellular pH changes. Afatinib, an irreversible inhibitor targeting EGFR and HER2 receptors, was chemically conjugated via a flexible linker to a methylpiperazine-functionalized naphthalimide fluorophore, enabling dual functionality: receptor targeting and pH-sensitive fluorescence.
Experimentally, AFNI-pH was applied to A549 lung cancer cells characterized by high EGFR expression and an acidic microenvironment. Fluorescence microscopy revealed selective probe accumulation in cancer cells versus normal cells, attributed to receptor-mediated uptake and pH-responsive signal activation. Cytotoxicity assays confirmed significant inhibitory effects on A549 proliferation, consistent with afatinib's pharmacological activity. Additionally, live-cell imaging tracked intracellular pH fluctuations during treatment, providing dynamic insights into tumor microenvironment modulation and potential drug resistance mechanisms.

Uemura I, et al. Immunology Letters, 2025, 275, 107024.

Afatinib was investigated for its effects on gastrointestinal mucosal immunity using a rat model. Male Wistar rats were administered afatinib at a dose of 5.2 mg/kg daily, both as a single 24-hour treatment and a prolonged 2-week regimen. To elucidate the immunological changes induced by afatinib, intestinal tissues were collected for quantitative polymerase chain reaction (qPCR) analysis, focusing on gene expression markers related to innate immunity, including α-defensin 5 and polymeric immunoglobulin receptor (pIgR). Concurrently, enzyme-linked immunosorbent assay (ELISA) quantified IgA concentrations in both intestinal mucosa and saliva, assessing alterations in acquired immunity. Results demonstrated that afatinib significantly suppressed α-defensin 5 and pIgR expression in the jejunum and ileum, indicating compromised innate mucosal defense. Conversely, intestinal and salivary IgA levels were elevated, with a significant positive correlation between the two, suggesting a compensatory activation of mucosal acquired immunity. These findings highlight afatinib's dual impact on mucosal immune components, emphasizing the utility of salivary IgA as a non-invasive biomarker for monitoring afatinib-induced gastrointestinal immune modulation during anticancer therapy.

Huang Y, et al. International Immunopharmacology, 2025, 152, 114368.

Afatinib was evaluated in combination with bevacizumab to treat a stage IIIA lung adenocarcinoma patient harboring a novel and rare EGFR exon 20 Q787L mutation. After initial tumor resection and chemotherapy with bevacizumab, disease progression prompted next-generation sequencing (NGS) of peripheral blood, which identified the Q787L mutation. Maintenance therapy commenced with first-generation EGFR-TKI icotinib plus bevacizumab; however, resistance developed after 8 months, and no secondary resistance mutations were detected.
Subsequently, oral afatinib was administered in combination with bevacizumab. The therapeutic regimen was monitored by serial computed tomography (CT) imaging, with partial remission observed after 3 months. The patient achieved a progression-free survival (PFS) exceeding 56 months, demonstrating durable clinical benefit without severe adverse effects. This prolonged response underlines the efficacy of afatinib's irreversible binding mechanism in overcoming resistance associated with uncommon EGFR mutations.

Rodon J, et al. ESMO Open, 2025, 10(5), 104545.

This study evaluated the clinical efficacy of afatinib, an irreversible ErbB family tyrosine kinase inhibitor, in patients harboring advanced solid tumors with NRG1 gene fusions, enrolled in the TAPUR phase II basket trial. Eligible patients presented measurable disease per RECIST criteria, ECOG performance status 0-2, and adequate organ function, with no standard treatment alternatives. Four patients (two colorectal cancer, one non-small-cell lung cancer, and one pancreatic adenocarcinoma) with confirmed NRG1 fusions received afatinib monotherapy. Efficacy analysis revealed one patient achieved a partial response, and two exhibited stable disease beyond 16 weeks, including one case with stable disease maintained for 134 weeks as of the last follow-up. Afatinib was well tolerated, with no reported grade 3-5 treatment-related adverse events. The application of afatinib targeted the aberrant NRG1 fusion-driven oncogenic signaling via irreversible blockade of the ErbB receptor family, demonstrating durable disease control across diverse tumor histologies. These results underscore afatinib's potential as a precision therapeutic agent in NRG1 fusion-positive malignancies, warranting further investigation in larger cohorts.